PNAS Nexus Publishes BreathBiomics

Zeteo Tech is thrilled to announce that its Director of Biomedical Programs’, Dapeng Chen, has had his groundbreaking work published in PNAS Nexus.

Using human exhaled breath for disease diagnosis has long been a dream. Zeteo has made significant strides by developing an advanced breath sampling system and sophisticated assay to measure key host response markers induced by respiratory infections.

In collaboration with JH Medicine, Zeteo has successfully applied its platform in critical care settings for early and rapid LRTI diagnosis. With its simplicity, this platform has the potential to become a point-of-care (POC) tool and could be expanded to other respiratory and lung conditions like COPD, CF, CAP, and asthma.

Diagnosing respiratory infections with breath | EurekAlert!

Breath analysis promises rapid diagnosis of lower respiratory infections (news-medical.net)

Proof-of-concept study shows breath analysis can diagnose respiratory infections (medicalxpress.com)

Zeteo Tech and Texas A&M University Awarded Phase I STTR Grant from the U.S. Department of Defense

Researchers collaborated to develop a prototype for an aerosol particle collector to integrate with microsensors for in-field threat monitoring

 

Sykesville, MD – September 19, 2024 – Zeteo Tech, Inc., the biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers and innovative human breath detection technologies, announced that it completed a Phase I Small Business Technology Transfer (STTR) program grant alongside Texas A&M University (TAMU, Department of Biological and Agricultural Engineering) to develop a modular aerosol sampler for microsensors to enable enhanced threat detection at the point of need.

The U.S. Department of Defense (DoD) issued a call for small, low-power, low-cost, networked aerosol collectors that, when integrated with microsensors, can be dispersed over an area for enhanced situational awareness. This would enable warfighters to monitor for threats such as toxic chemicals or pathogens in the field.

To meet this need, Zeteo has developed a modular microsensor that can be paired with TAMU’s wetted wall cyclone (WWC) technology, developed earlier for the Department of Homeland Security (DHS) or Zeteo’s own impactor module. Both technologies can be integrated with a modular microsensor based on the type of collection needed, including liquid, surface deposit, or air concentration. The proposed device would efficiently collect different particle sizes in large air volumes, deliver bioparticles in various liquid volumes while maintaining their culturability and DNA integrity, operate with a suite of potential sample collection fluids, and use components designed to be produced close to the point of need using advanced manufacturing techniques, and operate under the control of non-proprietary code.

“We are excited to have been selected for this award alongside our partners at Texas A&M to help the Department of Defense better protect soldiers in the field from biological and chemical threats,” said Dr. Wayne Bryden, President and Chief Executive Officer of Zeteo Tech. “By offering various sample formats and a modular design approach, our jointly developed solution enables the best technology to be fielded for many different use cases using a single portable device.”

“At Texas A&M we are very happy to be part of the Zeteo-Tech team. Joining this project is an exciting opportunity, and we look forward to working together and contributing to our shared goals for increased public safety,” said Dr. Maria King, Associate Professor and Director of the Center for Agricultural Air Quality Engineering and Science (CAAQES) at BAEN TAMU.

To learn more about Zeteo Tech and its technology, please visit www.zeteotech.com.

About Zeteo Tech

Zeteo Tech is a venture-backed biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers. Zeteo’s instruments identify airborne microbes, proteins, and lipids, and can be used to screen for infectious disease and other biothreats. Its innovative, patented and patent-pending time of flight mass spectrometry technology, digitalMALDI®, enables fully automated and near real-time identification of bio-threats in operational environments and dramatically lowers cost-of-ownership relative to the biomolecular reagent-based systems being currently deployed for biodefense applications. To learn more, visit www.zeteotech.com.

About Texas A&M University

The Center for Agricultural Air Quality Engineering and Science (CAAQES) at the Department of Biological and Agricultural Engineering addresses the needs for improved monitoring of public health emergencies by focusing on the collection, detection and tracking of hazardous bioaerosols including viruses and infectious particles with antimicrobial resistance. The sampling of bioaerosols using the wetted wall cyclone collectors developed at TAMU are conducted in industrial, agricultural, urban, and mass transport areas, such as hospitals, portable classrooms, dairy barns, chicken coops and meat processing facilities. The broader interest covers the computational and molecular modeling of bioaerosol transport and behavior, and the mitigation of their entrainment in ventilation airflow.

Media Contact

Kalyn Schieffer for Zeteo Tech

kos@anzupartners.com

Zeteo Tech Inc. Awarded $175K NOAA SBIR Phase I Grant to Develop Cutting-Edge Aerosol Detection System for Harmful Algal Blooms (HAB)

     Zeteo Tech, Inc. is proud to announce that it has been awarded a $175,000 Small Business Innovation Research (SBIR) Phase I grant from the National Oceanic and Atmospheric Administration (NOAA). This funding under grant number NA24OARX021G0001-T1-01 will support the development of a groundbreaking portable, fieldable, automated MALDI-TOF mass spectrometer designed to detect and quantify aerosolized toxins produced by harmful algal blooms (HAB).

     Harmful algal blooms have long been recognized as a significant and urgent threat to public health and the environment. The toxins produced by these algae not only contaminate food and water sources but also pose a lesser-known danger through aerosolization. Inhalation of these airborne toxins has been linked to increased hospitalization rates in coastal areas during HAB events. However, the transient nature of these aerosolized toxins has made it challenging to accurately assess exposure levels and their impact on human health.

     Zeteo Tech’s proposed solution addresses this critical gap by providing a rapid, accurate, and cost-effective method for screening the aerosol environment of coastal regions for a wide range of algal toxins. The portable mass spectrometer will serve as an early warning system, allowing local officials to make informed real-time decisions on emerging algal blooms, ultimately protecting coastal populations and economies.

     “We are thrilled to receive this NOAA SBIR Phase I award, which will enable us to advance our research and development of this detection system for aerosolized toxins,” said Tom McCreery, Chief Operations Officer and Chief Innovation Officer at Zeteo Tech. “This technology has the potential not just to improve but revolutionize the way we monitor and respond to harmful algal blooms, providing critical data that can safeguard public health and support future research into the effects of these toxins on human health.”

     The knowledge generated from this innovative system will not only enhance the detection of emerging HABs but also empower researchers and policymakers with the tools needed to mitigate their impact on coastal communities and industries.

     As Zeteo Tech embarks on this critical project, it looks forward to collaborating with NOAA and other stakeholders to bring this vital technology to fruition.

Zeteo Tech Awarded $1.87M DHS Science & Technology Directorate Contract to Develop and Test the Next Generation of the digitalMALDI® Real-Time Biological Threat Detection Technology

We are excited to share that the U.S. Department of Homeland Security has awarded Zeteo Tech a Phase III Small Business Innovation Research contract for $1.87M, with a potential value of up to $5.86 million. This new contract will fund the development and testing of digitalMALDI®, our next generation of sensor technology that enables real-time detection of aerosolized biological-threat agents that include bacteria, viruses, and toxins.

 

We look forward to assisting the DHS Science and Technology Directorate with its ongoing efforts to develop new tools for improving detection and response times to potential bioterrorism attacks or naturally occurring biological incidents. 

 

 

Read more in the press release here: https://www.businesswire.com/news/home/20231212977930/en/Zeteo-Tech-Awarded-1.87M-DHS-Science-Technology-Directorate-Contract-to-Develop-and-Test-the-Next-Generation-of-the-digitalMALDI%C2%AE-Real-Time-Biological-Threat-Detection-Technology

 

Zeteo Tech Expands IP Portfolio of Mass Spectrometry Technology

SYKESVILLE, Md.–(BUSINESS WIRE)–Zeteo Tech, Inc., the biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers and innovative human breath detection technologies, announced today the issuance of U.S. Patent No. 11658021, titled “Systems and Methods of Rapid and Autonomous Detection of Aerosol Particles.”

Using the patented “point-of-need” portable threat detection system, air samples can be automatically collected and analyzed for chemical and biological aerosolized threat agents, including bacteria, viruses, toxins, and chemicals such as fentanyl. The system’s sophisticated microfluidics, control architecture, threat agent library, and AI/ML software enable threat identification with high specificity and sensitivity within just a few minutes.

“This latest patent adds to Zeteo Tech’s robust IP portfolio protecting our technology that can perform rapid analysis of biological aerosols, including bacteria, viruses, and toxins,” said Dr. Wayne Bryden, President and CEO of Zeteo Tech. “Our mission is to collaborate with partners to commercialize our technology in order to help protect life and critical infrastructure by enabling rapid detection and accelerated initiation of emergency management protocols. For example, the system is capable of rapidly detecting new biological threats and being deployed in potential pandemic scenarios, similar to COVID-19.”

This patent marks the fourth U.S. Patent for Zeteo Tech on mass spectrometry technology, (3 granted and 1 allowed). In addition, Zeteo Tech has 12 mass spectrometry related foreign patents, (11 granted and 1 allowed).

Zeteo Tech has licensed its portable threat detection technology to Albuquerque-based bioaerosol surveillance company, BioFlyte. This agreement allows BioFlyte to use the technology for environmental sampling, detection, monitoring, and identification of chemical and biological threats within the defense and security market. BioFlyte is partnering with financial institutions, government organizations, like the Department of Defense, and airports, such as the Pittsburgh International Airport, to test and demonstrate the capabilities of its BioTOF™ z200 system.

“BioFlyte emerged from Zeteo Tech’s impressive portfolio of proprietary mass spectrometry technology, and our ongoing strategic partnership has been critical for our growth,” said BioFlyte CEO Todd Sickles. “With Zeteo’s support, BioFlyte is commercializing this groundbreaking rapid threat detection technology to protect people, critical infrastructure, and more.”

To learn more about Zeteo Tech and its technology, please visit www.zeteotech.com.

About Zeteo Tech
Zeteo Tech is a venture-backed biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers. Zeteo’s instruments identify airborne microbes, proteins, and lipids, and can be used to screen for infectious disease and other biothreats. Its innovative, patented and patent-pending time of flight mass spectrometry technology, digitalMALDI®, enables fully automated and near real-time identification of bio-threats in operational environments and dramatically lowers cost-of-ownership relative to the biomolecular reagent-based systems being currently deployed for biodefense applications. To learn more, visit www.zeteotech.com.

Contacts

Media
Brandon Reid for Zeteo Tech
bwr@anzupartners.com

 

https://www.businesswire.com/news/home/20231114380747/en/Zeteo-Tech-Expands-IP-Portfolio-of-Mass-Spectrometry-Technology

Zeteo Tech Awarded Competitive Grant From the National Institute of Allergy and Infectious Diseases

Small Business Innovation Research Program provides seed funding to fuel R&D for Zeteo
Tech’s Innovative Approach for Detecting Disease Markers in Human Breath.

Zeteo Tech, Inc. the biodefense and medical device company that has developed a
revolutionary new class of fieldable biological mass spectrometers and innovative human breath
detection technologies, has been awarded a National Institute Of Allergy And Infectious
Diseases (NIAID) Direct to Phase II Small Business Innovation Research (SBIR) grant for
$967,498, for the first year of a two year effort, totaling $1.9M, on “Noninvasive Diagnostic
Markers of Lower Respiratory Tract Infection in Mechanically Ventilated Patients”. Dr. Dapeng
Chen of Zeteo Tech, Inc. is the Principal Investigator for this grant.

The potential for human breath to serve as a non-invasive diagnostic tool has garnered
significant attention from healthcare professionals and industry experts alike. Lower respiratory
tract infections (LRTIs) are a common concern for ICU patients, particularly those with
mechanical ventilators. Zeteo Tech, Inc., in collaboration with the Johns Hopkins Hospital, will
investigate whether truncated proteoforms in human exhaled air can serve as a non-invasive
diagnostic marker for LRTIs, and early prediction of LRTI in mechanically ventilated patients. If
successful, this breakthrough research will provide clinicians with a valuable tool for decision-making
regarding antibiotic treatment, resulting in improved patient outcomes and reduced exposure to harmful
antibiotic treatments.

“We are absolutely delighted to win this highly competitive award from NIAID for our research
directed toward breath-based detection and characterization of LRTI. Dr. Chen, his team at
Zeteo Tech, and collaborators from Johns Hopkins developed highly convincing evidence for
this approach, leading to this NIAID award, and we are pleased to now add ASELL, LLC to the
team to support our commercialization efforts. This work is a critical component in Zeteo Tech’s
drive to transition technology investments by the Department of Defense and Department of
Homeland Security into medical tools that will revolutionize the diagnosis and treatment of lung
infections. Beyond LRTI, we expect these tools to evolve into platforms for point-of-care
diagnosis and assessment of multiple disease states and conditions.” said Wayne Bryden,
President and CEO of Zeteo Tech, Inc.

The work in this press release is supported by the National Institute Of Allergy And Infectious Diseases of the
National Institutes of Health under Award Number R44AI177245. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the National Institutes of Health

Zeteo Tech Awarded Competitive Grant From the National Science Foundation

SYKESVILLE, Md.–(BUSINESS WIRE)–Zeteo Tech, the biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers, has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $256,000. The grant will be leveraged for research and development on its COVID-19 Fully Automated Disinfection System (CFADS) to help rapidly return aircraft and subway cars safely to service and disinfect public gathering spaces.

https://www.businesswire.com/news/home/20210817005218/en/Zeteo-Tech-Awarded-Competitive-Grant-From-the-National-Science-Foundation

Zeteo Tech Appoints Former U.S. Assistant Secretary of Defense Andrew Weber to Board of Directors

SYKESVILLE, Md., July 29, 2020 /PRNewswire/ — Zeteo Tech, the biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers, today announced that the Honorable Andrew Weber has joined its Board of Directors. Mr. Weber served as the Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs under President Obama.

“Andy has dedicated much of his professional career working to strengthen our Nation’s security and response to nuclear, chemical, and biological threats,” said Wayne Bryden, PhD, President and CEO of Zeteo Tech. “We are delighted that he is joining the Board, and his unmatched wealth of knowledge and experience will be greatly utilized as Zeteo continues to grow its commercial and government offerings.”

Zeteo Tech’s proprietary digitalMALDI® technology pushes mass spectrometry innovation to a new level of sensitivity and specificity, enabling its instruments to obtain biomarker measurements from individual particles in the bioaerosol and then complete a biomarker-specific molecular identification in seconds. A combination of proprietary bioaerosol processing and MALDI mass spectrometry enables the technology’s ground-breaking advances to eliminate environmental background. By discretizing the sample in time, the analysis is exceptionally fast, sensitive and specific.

In addition to Mr. Weber’s public service as the Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs, he was a driving force behind Nunn-Lugar Cooperative Threat Reduction efforts to remove weapons-grade uranium from Kazakhstan and Georgia and nuclear-capable MiG-29 aircraft from Moldova, to reduce biological weapons threats, and to destroy Libyan and Syrian chemical weapons stockpiles. Mr. Weber also coordinated leadership of the international Ebola response for the U.S. Department of State.

Prior to joining the Pentagon as Advisor for Threat Reduction Policy in December 1996, Mr. Weber was posted abroad as a U.S. Foreign Service Officer in Saudi Arabia, Germany, Kazakhstan, and Hong Kong. Mr. Weber is an independent consultant and a Strategic Advisor for Ginkgo BioWorks. He serves on the Boards of Healthcare Ready and the Arms Control Association, and the James Martin Center for Non-proliferation Studies International Advisory Council.

Mr. Weber taught at the Georgetown University Graduate School of Foreign Service for seven years and was a Senior Fellow at the Harvard Kennedy School’s Belfer Center for Science and International Affairs. Mr. Weber graduated from Cornell University and holds a Master of Science in Foreign Service (MSFS) degree from Georgetown University. He is a member of the Council on Foreign Relations and a Senior Fellow at the Council on Strategic Risks, a non-partisan, non-profit think tank working against existential threats.

For more information about Zeteo Tech, please visit https://zeteotech1.wpengine.com.

About Zeteo Tech
Zeteo Tech is a venture-backed biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers. Its instruments identify airborne microbes, proteins and lipids, and can be used to screen for infectious disease and other bio-threats. Its innovative and patent-pending time of flight mass spectrometry technology, digitalMALDI®, enables fully-automated and near real-time identification of bio-threats in operational environments and dramatically lowers cost-of-ownership relative to the biomolecular reagent-based systems being launched for biodefense applications.

CONTACT
Rob Haralson for Zeteo Tech
rhh@anzupartners.com, (202) 674-6679